iCAD, Inc. announced that it will showcase its breast health AI technologies at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, December 1-5. Key highlights include the recent FDA-cleared ProFound Detection Version 4, clinical research presentations, and a new partnership with Cascaid Health to expand access to AI-driven breast health solutions. iCAD and Cascaid Health Partner to Expand Access to AI-Driven Breast Health: In alignment with their vision to enable all women to access to AI-powered breast health services, iCAD and Cascaid Health will unveil their collaboration to integrate the ProFound AI Breast Health Suite into Cascaid?s leading edge digital health marketplace and access to care platform. Scheduled for beta launch in First Quarter 2025, this partnership between iCAD and Cascaid Health will launch ProFound Health, a virtual care model powered by Cascaid. ProFound Health will enable women who have not otherwise received an AI-read on their screening mammogram to access iCAD?s advanced breast health technology. The initiative reflects both companies? dedication to democratizing access to life-saving technology and creating a world where cancer can?t hide. ProFound Health partnership will offer virtual second reads of mammograms leveraging ProFound AI Breast Health Suite, an AI service providing patients without access to AI an opportunity to receive enhanced breast health insights. The initial service will include a second read detection, breast density assessment, and cancer risk evaluation from a Cascaid-affiliated specialist network of clinical experts in women?s health through Cascaid?s seamlessly integrated digital platform. By combining AI insights with expert clinical reviews, ProFound Health ensures that patients everywhere, regardless of location, can receive precision screening and personalized care. Advancing Next Generation AI Breast Health Solutions at RSNA 2024: In addition to ProFound Health, iCAD will feature its ProFound Detection Version 4.0, which recently received FDA clearance. This next-generation AI solution enhances breast cancer detection by incorporating prior exams into current analysis, improving the detection of aggressive cancers by 22%, reducing cases with no marks by 18%, and providing clinicians with more reliable insights for better decision-making. ICAD?S RSNA 2024 Program Highlights: AI-Powered Insights: Advancing Cancer Detection: Oral Abstract Presentation:Real World Effect of Artificial Intelligence on Histopathology and Stage in Breast Cancer Screening. Presenter: Kathy Schilling, M.D., Boca Raton Regional Hospital. When: December 1, 2024 | 10:30?11:30 AM . Where: S406A: S2-SSBR01-6. Details: Dr. Kathy Schilling discusses the experience with tenured radiologists on how the current use of ProFound AI improves cancer detection, even in women with dense breast tissue, compared to their performance prior to the implementation of AI. In addition, she will describe the decrease in the mean size and stage of cancers after the implementation, along with an increase in the diagnosis of lobular cancers. AI Theater Presentation: The Thin White Line: Which Calcifications Matter? Advances in AI Breast Cancer Detection. Presenter: Chirag R. Parghi, M.D., M.B.A., Solis Mammography. When: December 3, 2024 | 1:00?1:20 PM. Where: AI Showcase Theater (South Hall A), Booth 5536. Details: A look at how ProFound Detection?s next-generation capabilities reduce uncertainty in interpreting calcifications on a mammogram by displaying 20% fewer marks related to vascular calcifications and 51% fewer marks related to non-vascular calcifications, leading to enhanced precision and accuracy.
